We are proud to present the 7th Annual AI in Drug Discovery Conference on 9th-10th March 2026, in London, UK. Join us for the biggest AI in drug discovery event in the UK, that brings together the highest number of big pharma speakers for focused discussions and networking.
With the global AI in drug discovery market expected to reach 7.94 billion by 2030, AI is leading technological advancement across the pharmaceutical sector, and is expected to transform pre-clinical drug discovery.
Are you ready for this transformative period?
With ever-increasing pressures on drug pipelines, strategies for faster, cheaper and more successful R&D are required - this conference will showcase how AI-driven technologies are turning these strategies into reality. Through detailed case-study presentations and interactive panel-discussion sessions, we will navigate data volume and quality challenges, create strategies for increasing efficiency of R&D, and explore the impact of generative AI on drug discovery pipelines.
This year's event will feature hot topics including applications of AI/ML within target identification and computational drug design, the impact of generative AI on ways of working and clinical updates from the first AI-designed drug candidates.
Our two-day agenda offers you peer-to-peer networking with industry experts from an extensive selection of big pharma and breakthrough biotech's in the field, including directors and heads of informatics, data & AI, molecular design, and computational chemistry. Don't miss the chance to hear the latest advancements from leaders in the industry!
Speakers
- Anna Macintyre, Senior Data Scientist, Novo Nordisk
- Christoph Grebner, Senior Principal Scientist, Sanofi
- Graeme Robb, Director, Computational Chemistry, AstraZeneca
- Haruna Iwaoka, Head, Advanced Modeling & Assays, Innovation Core Lab, Astellas Pharma
- James Lumley, Head of Cheminformatics, GSK
- Le Mu, MLOps Lead, Computational Sciences Center of Excellence, gRED, Roche
- Lewis Vidler, Senior Director - Structure Based Drug Design, Eli Lilly and Company
- Martin Buttenschoen, Researcher, University of Oxford
- Martin Redhead, Associate Vice President Primary Pharmacology, Recursion
- Paul Mortenson, Senior Research Associate, Computational Chemistry, Astex Technology
- Pedro J. Ballester, Royal Society Wolfson Fellow & Associate Professor, Department of Bioengineering, Imperial College London, UK
- Peter Clark, VP, Computational Drug Design, Novo Nordisk
- Petrina Kamya, Global Head of AI Platforms, VP, Insilico Medicine
- Reiko Wada, Senior Scientist, Astellas Pharma Inc.
- Sammeli Liikkanen, Director, Digital Medicine, Orion Corporation Orion Pharma
- Simone Fulle, Head CADD, Basel, Novartis
- Teresa de Haro, Principal Scientist, UCB
- Thierry Dorval, Head of Data Sciences & Data Management, Servier Pharmaceuticals
- Tim Hohm, Associate Director Digital Science External Partnerships, Novo Nordisk
- Venkatesh Pilla Reddy, Senior Director, Global PKPD and Pharmacometrics, Eli Lilly
- Yogesh Sabnis, Director of Lead Design, UCB Biopharma srl
Please fill in your name and email to receive the Conference Agenda of this event.
Venue
Hilton London Kensington
179-199 Holland Park Ave, Kensington, W11 4UL
London, UK
